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Breast cancer is the most common cancer in women
worldwide (Parkin, 2001). In England and Wales at the end of
the 1990s, approximately 36000 new cases were diagnosed each
year, representing 30% of the annual total of 120000 cases. The
number of cases exceeds the combined total for the second and
third most common cancers in women, those of the large bowel
(14700 cases, 12%) and lung (12600 cases, 10%). Breast cancer in
men is comparatively uncommon, and is not considered
further here.
During the 1970s and 1980s, age-standardised incidence
increased on average by approximately 2% each year (Quinn
et al, 2001). The NHS breast-screening programme began in 1988,
covering women aged 50–64 years and using single mediolateral
oblique view mammography and a 3-year interval between screens.
During the prolonged prevalence round, overall breast cancer
incidence increased by approximately 20%; it subsequently
declined, but then rose again, and by the late 1990s, incidence
was some 7% higher than at the peak in the early 1990s (Office for
National Statistics, 2003). Part of the increase, possibly as much as
20% in post-menopausal women, may have resulted from the
increasing use of hormone replacement therapy (HRT) in the
1990s (Beral et al, 1997).
After the exclusion of in situ tumours, we analysed the data for
382277 women diagnosed with a first, primary, malignant
neoplasm of the breast in England and Wales during the 14-year
period 1986–1999 and followed up to 31 December 2001, some
89% of those eligible for analysis. Approximately 6.1% of women
who were otherwise eligible were excluded with zero recorded
survival (date of diagnosis same as date of death): most of these
women will have been registered from a death certificate only
(DCO), and their duration of survival is unknown, but they could
not be reliably distinguished in these data from women with true
zero survival. The proportion of women excluded from analysis as
DCO records was very similar in all socioeconomic groups. A
further 2.4% of women were excluded because it was not their first
primary cancer: for one-third of these women, the previous cancer
was also a breast cancer, diagnosed before 1986.
Major shifts in the morphological distribution of breast
cancers have occurred over the last 30 years. The proportion
described as an adenocarcinoma has been falling steadily,
from 36% in the early 1970s (Coleman et al, 1999) to 6% in these
data by the late 1990s. In the early 1970s, ductal, lobular and
medullary tumours comprised less than 10% of all breast cancers,
but by the late 1990s this figure had reached 75%, ductal
carcinomas alone comprising 60% of all breast cancers. The
proportion of tumours with unspecified morphology has con-
tinued to fall, from 47% in 1971–1975 to 30% in 1986–1990 and
less than 5% in 1996–1999. Even this massive improvement in data
quality cannot account for the overall increase in ductal, lobular
and medullary tumours.
SURVIVAL TRENDS
For women diagnosed in the late 1990s, relative survival 1 year
after diagnosis had reached 94%, a deprivation-adjusted average
increase of 2.0% every 5 years since 1986–1990 (Table 1, Figure 1).
Five-year survival had reached 80%, an average increase of 6.2%
every 5 years over the same period. Ten-year survival rose even
more markedly, by almost 10%, from 58% for women diagnosed
during 1986–1990 to 67% for women diagnosed during 1991–1995,
just 5 years later.
This trend is confirmed by hybrid analysis of the survival
probabilities observed during 2000–2001 (Brenner and Rachet,
2004), with a predicted 10-year survival of 73% for women
diagnosed at about that time.
DEPRIVATION
The deprivation gap in 5-year and 10-year survival for
women diagnosed during 1986–1990 was close to 6% (Table 2).
The gap in 1-year survival was smaller, at approximately 3%.
Survival has increased in all groups of the population, but
the difference between rich and poor has not changed at all
(Figure 2).
Short-term predictions of survival by socioeconomic group,
again using hybrid analysis of the probabilities of survival
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www.bjcancer.comobserved during 2000–2001, do not suggest any imminent change
in the significant deprivation gap in survival between affluent and
deprived women.
COMMENT
Breast cancer survival rose rapidly and significantly during the
1990s, and although the difference in survival between affluent and
deprived women did not improve, at least it did not widen, in
contrast to the widening deprivation gap in survival seen for most
other malignancies (Coleman et al, 2004).
The trends in breast cancer survival among women diagnosed
up to 1999 extend the continuing increase seen since the 1970s and
1980s, when 1-year survival rose from 84 to 90% and 5-year
survival from 54 to 68% (Coleman et al, 1999). Women aged 50–64
years were invited for mammographic screening from 1988, and
5-year survival for women in the age range 50–69 years rose by
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Women 90.2 (90.0, 90.4) 92.5 (92.3, 92.6) 94.4 (94.2, 94.5) 2.0** (1.7, 2.3) 94.9 (94.7, 95.1)
5 years Women 68.3 (68.0, 68.6) 75.2 (74.9, 75.4) 79.8 (79.5, 80.1) 6.1** (5.5, 6.7) 80.9 (80.5, 81.3)
10 years Women 57.5 (57.1, 57.8) 67.0 (66.7, 67.4) 9.6** (8.4, 10.9) 72.5 (72.1, 73.0)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by calendar
period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with cohort
or complete approach (1986–1990, 1991–1995, 1996–1999) or hybrid
approach (2000–2001) (see Rachet et al, 2008).
60
70
80
90
100
5
-
y
e
a
r
 
r
e
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
Affluent 2 3 4 Deprived
Deprivation category
2000–2001
1996–1999
1991–1995
1986–1990
Women
Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Women  3.1** ( 3.6,  2.5)  2.9** ( 3.4,  2.5)  2.6** ( 3.1,  2.2) 0.2 ( 0.1, 0.6)  2.7** ( 3.2,  2.1)
5 years Women  5.6** ( 6.5,  4.7)  5.6** ( 6.4,  4.9)  5.8** ( 6.7,  4.8)  0.1 ( 0.8, 0.6)  5.2** ( 6.3,  4.1)
10 years Women  5.6** ( 6.6,  4.6)  5.9** ( 6.9,  4.9)  0.3 ( 1.7, 1.2)  6.1** ( 7.5,  4.8)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
Survival from cancer of the breast in women
MJ Quinn et al
S54
British Journal of Cancer (2008) 99(S1), S53–S55 & 2008 Cancer Research UK7–10% between 1986 and 1993, much more than for either older
women (less than 2%) or younger women (less than 4%) (Coleman
et al, 2000a,b). By the late 1990s, however, this difference in age-
specific trends had vanished (Rachet et al, 2005). Earlier diagnosis
following mammography will increase survival time even if death
is not delayed by treatment (lead-time bias), but the age-specific
survival trends suggest that lead-time bias is unlikely to be the sole
explanation for the overall increase in survival.
Further analysis of our data shows that the incidence of breast
cancer rose more rapidly among affluent women than among
deprived women between 1986 and 1999 (Figure 3). If the more
marked increase in incidence among affluent women were solely
attributable to higher compliance with screening, and if we accept
the impact of screening on survival, then the deprivation gap in
relative survival would also have been expected to increase, and it
did not (Figure 2). The incidence trends may therefore also reflect
deprivation-specific trends in risk factors, including reproductive
history and the use of HRT.
Despite the increase in breast cancer incidence during the 1990s,
mortality has fallen in all age groups (Quinn et al, 2001). The larger
falls in mortality in the screened age groups indicate that by the
late 1990s, approximately one-third of the 20% overall reduction in
breast cancer mortality was directly attributable to screening,
although most of the fall in mortality was attributable to a
combination of earlier diagnosis outside the screening programme,
increasingly widespread use of tamoxifen since the 1980s and
other, more recent improvements in chemotherapy, and
more indirect effects of the screening programme, such as
improvement in the organisation and delivery of services to
symptomatically detected cases as well as screen-detected cases
(Blanks et al, 2000).
We have recently predicted that long-term survival up to 20
years after diagnosis is likely to continue improving. The largest
predicted increase also affects women aged 50–69 years at
diagnosis (Woods et al, 2007).
For more than 30 years, breast cancer survival in England and
Wales has been consistently lower in women from deprived areas,
even after adjustment for higher background mortality in the more
deprived areas. In the 1970s and early 1980s, the deprivation gap in
5-year survival was approximately 10%. The gap fell to 6% for
women diagnosed during 1986–1990, but it has not changed any
further since that time. This is remarkable because, for most
cancers for which 5-year survival has improved as rapidly as it has
done for breast cancer (approximately 6% every 5 years), the
deprivation gap in survival has also widened considerably (Cole-
man et al, 2004). The deprivation gap in relative survival is
adjusted for the wide socioeconomic differences in background
mortality, and for changes over time in those differentials.
Differences in crude survival (unadjusted for background mortal-
ity; data not shown) are actually wider than those for relative
survival. The lack of improvement in the deprivation gap in
relative survival is therefore not an artefact of failure to adjust for
changes in background mortality among women with breast
cancer.
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Figure 3 Trends in the age-standardised incidence of breast cancer
in women aged 15–99 years, by deprivation group: England and
Wales, 1986–1999.
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